NCT02159131 - Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Infections, Human Immunodeficiency Virus and Hepatitis

Interventions

DRUG

Ethinyl Estadiol

EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water

DRUG

Levonorgestrel

LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water

DRUG

GSK1265744

GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water

Trial Locations (1)

GSK Investigational Site, London